Short Interest in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Grows By 161.3%

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 500,700 shares, a growth of 161.3% from the January 31st total of 191,600 shares. Based on an average daily trading volume, of 3,200,000 shares, the short-interest ratio is presently 0.2 days. Approximately 6.4% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals in a report on Friday, February 14th. They issued a "hold" rating on the stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Cumberland Pharmaceuticals stock. Two Sigma Investments LP raised its holdings in shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Free Report) by 94.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,649 shares of the specialty pharmaceutical company's stock after purchasing an additional 18,271 shares during the period. Two Sigma Investments LP owned 0.27% of Cumberland Pharmaceuticals worth $89,000 as of its most recent SEC filing. Institutional investors own 15.51% of the company's stock.

Remove Ads

Cumberland Pharmaceuticals Trading Up 17.7 %

CPIX stock traded up $0.91 during trading on Tuesday, reaching $6.05. The company had a trading volume of 401,060 shares, compared to its average volume of 849,868. The business has a 50 day moving average of $3.45 and a 200 day moving average of $2.10. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.13 and a quick ratio of 0.99. The company has a market cap of $84.95 million, a P/E ratio of -7.86 and a beta of 0.12. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.19.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The specialty pharmaceutical company reported ($0.03) earnings per share for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.